Physicians' Academy for Cardiovascular Education

SGLT2 inhibition in cardiology: What a cardiologist needs to know

Aug. 28, 2017 - Barcelona, Spain - Naveed Sattar, MD, Oxford, United Kingdom - PACE-CME symposium held at ESC 2017

This lecture was part of a CME accredited symposium: Modern management of diabetes in cardiology: impact of SGLT2 inhibition on cardiovascular outcomes and heart failure held at ESC 2017 in Barcelona

Video navigation menu

  • Treatment with empagliflozin in the EMPA-REG OUTCOME trial showed a substantial reduction in CV death 02:10
  • Empagliflozin improves kidney function, leading to generalized decongestion, thereby benefitting the heart 04:29
  • What are the potential mechanisms for the observed benefits on the cardio-renal axis? 06:15
  • The guidelines recommend using empagliflozin in patients with diabetes and CVD 09:21
  • Comparing the EMPA-REG OUTCOME and CANVAS study; results with empagliflozin and canagliflozin 11:12

Educational information

The educational objectives of this symposium were to:

Faculty

Naveed Sattar, MD is Professor of Metabolic Medicine, OCDEM, University of Oxford. He is an academic (active clinically) experienced in biomarker studies/trials investigating the causes, prevention and management of diabetes, obesity and heart disease. He has authored or co-authored over 650 published papers, has received several national and international prizes for his research, and is in the top 1% of cited clinical academics in the world according to the Thomson Reuters 2016 Highly Cited Researcher list.

CME Accreditation

This programme was accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s).

Disclosures

This symposum was supported by an unrestricted educational grants provided by Boehringer-Ingelheim/Lilly

Biography, abstract and key slides View and download slides